These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 19190805)

  • 1. Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure.
    Claus RA; Bockmeyer CL; Budde U; Kentouche K; Sossdorf M; Hilberg T; Schneppenheim R; Reinhart K; Bauer M; Brunkhorst FM; Lösche W
    Thromb Haemost; 2009 Feb; 101(2):239-47. PubMed ID: 19190805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ratio of von Willebrand factor propeptide to ADAMTS13 is associated with severity of sepsis.
    Fukushima H; Nishio K; Asai H; Watanabe T; Seki T; Matsui H; Sugimoto M; Matsumoto M; Fujimura Y; Okuchi K
    Shock; 2013 May; 39(5):409-14. PubMed ID: 23481506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis.
    Reuken PA; Kussmann A; Kiehntopf M; Budde U; Stallmach A; Claus RA; Bruns T
    Liver Int; 2015 Jan; 35(1):37-45. PubMed ID: 25113276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The balance between von-Willebrand factor and its cleaving protease ADAMTS13: biomarker in systemic inflammation and development of organ failure?
    Claus RA; Bockmeyer CL; Sossdorf M; Lösche W
    Curr Mol Med; 2010 Mar; 10(2):236-48. PubMed ID: 20196724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension.
    van den Born BJ; van der Hoeven NV; Groot E; Lenting PJ; Meijers JC; Levi M; van Montfrans GA
    Hypertension; 2008 Apr; 51(4):862-6. PubMed ID: 18332284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of plasma von Willebrand factor and its cleaving protease ADAMTS13 in patients with atrial fibrillation.
    Freynhofer MK; Gruber SC; Bruno V; Höchtl T; Farhan S; Zaller V; Wojta J; Huber K
    Int J Cardiol; 2013 Sep; 168(1):317-25. PubMed ID: 23041092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADAMTS13 related markers and von Willebrand factor in plasma from patients with thrombotic microangiopathy (TMA).
    Kobayashi T; Wada H; Nishioka N; Yamamoto M; Matsumoto T; Tamaru T; Nomura S; Masuya M; Mori Y; Nakatani K; Nishikawa M; Katayama N; Nobori T
    Thromb Res; 2008; 121(6):849-54. PubMed ID: 17900666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP.
    Schwameis M; Schörgenhofer C; Assinger A; Steiner MM; Jilma B
    Thromb Haemost; 2015 Apr; 113(4):708-18. PubMed ID: 25503977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction.
    Matsukawa M; Kaikita K; Soejima K; Fuchigami S; Nakamura Y; Honda T; Tsujita K; Nagayoshi Y; Kojima S; Shimomura H; Sugiyama S; Fujimoto K; Yoshimura M; Nakagaki T; Ogawa H
    Am J Cardiol; 2007 Sep; 100(5):758-63. PubMed ID: 17719316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidation of Met1606 in von Willebrand factor is a risk factor for thrombotic and septic complications in chronic renal failure.
    De Filippis V; Lancellotti S; Maset F; Spolaore B; Pozzi N; Gambaro G; Oggianu L; Calò LA; De Cristofaro R
    Biochem J; 2012 Mar; 442(2):423-32. PubMed ID: 22091998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced ADAMTS13 activity is associated with thrombotic risk in systemic lupus erythematosus.
    Martin-Rodriguez S; Reverter JC; Tàssies D; Espinosa G; Heras M; Pino M; Escolar G; Diaz-Ricart M
    Lupus; 2015 Oct; 24(11):1143-9. PubMed ID: 25824235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myocardial infarction as a systemic prothrombotic condition evidenced by increased von Willebrand factor protein over ADAMTS13 activity in coronary and systemic circulation.
    Horii M; Uemura S; Uemura M; Matsumoto M; Ishizashi H; Imagawa K; Iwama H; Takeda Y; Kawata H; Nakajima T; Fujimura Y; Saito Y
    Heart Vessels; 2008 Sep; 23(5):301-7. PubMed ID: 18810578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis.
    Matsuyama T; Uemura M; Ishikawa M; Matsumoto M; Ishizashi H; Kato S; Morioka C; Fujimoto M; Kojima H; Yoshiji H; Takimura C; Fujimura Y; Fukui H
    Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S27-35. PubMed ID: 17331163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced ADAMTS13 in children with severe meningococcal sepsis is associated with severity and outcome.
    Bongers TN; Emonts M; de Maat MP; de Groot R; Lisman T; Hazelzet JA; Leebeek FW
    Thromb Haemost; 2010 Jun; 103(6):1181-7. PubMed ID: 20390223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia.
    Molvarec A; Rigó J; Bõze T; Derzsy Z; Cervenak L; Makó V; Gombos T; Udvardy ML; Hársfalvi J; Prohászka Z
    Thromb Haemost; 2009 Feb; 101(2):305-11. PubMed ID: 19190814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome.
    Hugenholtz GC; Adelmeijer J; Meijers JC; Porte RJ; Stravitz RT; Lisman T
    Hepatology; 2013 Aug; 58(2):752-61. PubMed ID: 23468040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor.
    Bockmeyer CL; Claus RA; Budde U; Kentouche K; Schneppenheim R; Lösche W; Reinhart K; Brunkhorst FM
    Haematologica; 2008 Jan; 93(1):137-40. PubMed ID: 18166799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of plasma von Willebrand factor-cleaving protease (ADAMTS13) antigen levels in patients with coronary artery disease.
    Miura M; Kaikita K; Matsukawa M; Soejima K; Fuchigami S; Miyazaki Y; Ono T; Uemura T; Tsujita K; Hokimoto S; Sumida H; Sugiyama S; Matsui K; Yamabe H; Ogawa H
    Thromb Haemost; 2010 Mar; 103(3):623-9. PubMed ID: 20135067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation.
    Reiter RA; Varadi K; Turecek PL; Jilma B; Knöbl P
    Thromb Haemost; 2005 Mar; 93(3):554-8. PubMed ID: 15735809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preserved Expression of mRNA Coding von Willebrand Factor-Cleaving Protease ADAMTS13 by Selenite and Activated Protein C.
    Ekaney ML; Bockmeyer CL; Sossdorf M; Reuken PA; Conradi F; Schuerholz T; Blaess MF; Friedman SL; Lösche W; Bauer M; Claus RA
    Mol Med; 2015 Apr; 21(1):355-63. PubMed ID: 25860876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.